Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas

Table 1 Summary of chromodomain-helicase-DNA binding protein 5, 7 and mixed lineage kinase domain-like protein biomarkers in pancreatic adenocarcinoma

Biomarker	Pathway affected	Biomarker type for pancreatic cancer from literature and studies? (prognostic, predictive, diagnostic)	Mechanism of action	Other cancers	Comments
CHD5[33]	DDR	Prognostic	Tumor suppressor gene. Binds to histone 3	Epigenetically silenced in neuroblastoma[37], colorectal cancer[38], breast cancer[39], cervical cancer[39], hepatocarcinoma[39], gastric cancer[40] and lung cancer[41]. Mutations found in head and neck squamous cell carcinoma[42], prostate cancer[43], ovarian cancer[44], ovarian clear cell carcinoma[45], cutaneous melanoma[46], hepatocellular carcinoma[47], neuroblastoma[48], breast and colorectal cancer[49]	Low expression correlates with worse clinical outcomes
CHD7[66]	DDR	Prognostic	Interacts with SOX2 to regulate gene expression	-	Decreased expression is associated with improved clinical outcomes
MLKL[74]	Necroptosis	Prognostic	Forms necrosis- inducing complex called a “necrosome” along with RIPK1 and RIPK3	Ovarian[75]	Low expression is associated with worse clinical outcomes

DDR: DNA damage response pathway; SOX2: (Sex Determining Region Y)-Box 2; RIPK1: Receptor-interacting serine/threonine-protein kinase 1; RIPK3: Receptor-interacting serine/threonine-protein kinase 3.